top of page
Executive Spotlights

Immatics NV and Moderna Forge Billion-Dollar Collaboration to Revolutionize Cancer Therapy

Cambridge, MA, September 11, 2023 (Reuters) -- German drug developer, Immatics NV, is set to receive an impressive initial payment of $120 million. Immatics NV stands to benefit from an array of development, regulatory, and commercial milestone payments that have the potential to exceed a staggering $1.7 billion.


Read full article here.

Recent Posts

See All

AxoSim appoints Alif Saleh as CEO

New Orleans, LA, June 14, 2024 (Indian Pharma Post) -- AxoSim, a life science firm specializing in lab-grown human brains, has appointed Alif Saleh as its new CEO. Salef, a company builder, brings e

Comments


Life Science Headlines
bottom of page